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Abstract
Purpose of Review To present the latest evidence related to the predictors of urinary tract infections (UTIs) and urosepsis after
ureteroscopy (URS) for stone disease.
Recent Findings Our review suggests that almost half of all post-URS complications are related to infectious complications
although reported rates of urosepsis were low. The use of antibiotic prophylaxis, treatment of pre-operative UTI, and low
procedural time seem to reduce this risk. However, the risk is higher in patients with higher Charlson comorbidity index, elderly
patients, female gender, long duration of pre-procedural indwelling ureteric stents and patients with a neurogenic bladder and
with high BMI.
Summary Infectious complications following ureteroscopy can be a source of morbidity and potential mortality. Although
majority of these are minor, efforts must be taken to minimise them especially in high-risk patients. This includes the use of
prophylactic antibiotics, limiting stent dwell and procedural time, prompt identification and treatment of UTI and urosepsis, and
careful planning in patients with large stone burden and multiple comorbidities.
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Introduction
The prevalence and incidence of kidney stone disease (KSD)
have been increasing globally in the last 50 years [1]. In
England, national data from 2006/2007 to 2013/2014 shows
that there has been an increase in the lifetime prevalence of
urolithiasis-based admissions and intervention from the histor-
ically reported 10 to 14% [2]. This is due to a rise in metabolic
syndrome, lifestyle changes but also partly due to global
warming as higher monthly ambient temperatures are positive-
ly associated with incidence of kidney stones [3•]. Treatment
options include ureteroscopy (URS), shock wave lithotripsy
(SWL) and percutaneous nephrolithotomy (PCNL) [4–6].
Published data from the last 15–20 years has shown a steep
rise in the use of URS and PCNL, while the use of SWL and
open surgery have declined [7•, 8].Moreover, URS has shown
to achieve higher stone-free rates than SWL and lower com-
plication rates compared with PCNL [4, 5].
Following URS, the overall rate of complications varies
between 9 and 25% although the majority of these are minor
and does not require intervention [9–11]. Infectious complica-
tions ranging from fever, systemic inflammatory response
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syndrome to urinary tract infection (both upper and lower) are
some of the more common post-ureteroscopy complications,
alongside haematuria and post-operative pain [11], with over-
all complication rates of up to 25% [12, 13•]. As ureteroscopy
is being performed in increasing numbers with the rising prev-
alence of KSD [2], it is to be expected that the rate of infec-
tious post-URS complications is consequently also increasing
[13, 14]. Similarly, the indications of ureteroscopy have ex-
panded, and it is now being performed for high-risk patients
such as solitary kidneys, paediatrics, pregnancy and upper
tract tumours [15–17].
In the literature, there are many small, medium and high-
volume prospective studies that have reported on the infec-
tious complications following URS for renal stone disease
[18–29]. Some studies have also looked at the risk factors
for urinary infections following ureteroscopy and advised on
strategies to reduce these risks. However, there is a lack of data
on the predictors of post-ureteroscopy infectious complica-
tions. We conducted a systematic review of literature looking
at the infection-related post-ureteroscopy complications re-
ported from high-volume centres.
Materials and Methods
Search Strategy and Study Selection
The systematic reviewwas performed according to the Cochrane
review guidelines and in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) checklist from January 2009 to November 2019 for
English language articles [30, 31]. The search strategy was
conducted to find relevant studies from the Medline,
EMBASE, Scopus, Cochrane Library, CINAHL,
Clinicaltrials.gov, Google Scholar and individual urologic
journals. The search terms included ‘ureteroscopy’, ‘URS’,
‘complications’, ‘urosepsis’, ‘urinary tract infection’, ‘UTI’, ‘ret-
rograde intrarenal surgery’, ‘RIRS’, ‘systemic inflammatory re-
sponse syndrome’, ‘SIRS’, ‘infection’, ‘bacteraemia’, ‘mortality’
and ‘death’.
A cutoff of 400 patients was set to include studies from
high-volume endourological centres with relevant
endourological experience. All original studies were included
and where more than one article was available, the study with
the longest follow-up was included. The review was carried out
by two reviewers (SC and BKS) independently, and all discrep-
ancies were resolved with mutual agreement.
Evidence Acquisition
Inclusion criteria:
1. Studies reporting on infectious complications post-
ureteroscopy
2. Studies from high-volume endourological centres
reporting on a minimum of 400 patients
3. Studies in English language
Exclusion criteria:
1. Reviews, commentaries or studies with less than 400
patients
2. Paediatric population
3. Ureteroscopy performed for non-stone disease
Fig. 1 PRISMA flowchart of the
included studies
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Table 2 Details of infectious and non-infectious complications from the included studies
Paper Number of
procedures (N)
Stone length
(mm) (range)
Stone location Ureteral access
sheath utilisation
(n) (%)
Mean operating
time (mins)
Stone-
free
rate (%)
Non infective
complications
(n) (%)
Pricop C, Dorobăt C,
Puia D et al.
473 Majority 6–8 Ureteric—100% N/S N/S N/S N/S
Martov A, Gravas S,
Etemadian M et al.
2650 N/S Ureteric—85.7%;
renal—13.2%
N/S 51.3 90.80% 4.75%—
intraoperative
Özsoy M, Acar Ö,
Sarica K et al.
927 N/S N/S N/S 41.4 87% 15.20%
Moses RA, Ghali FM,
Pais VM Jr. et al.
550 N/S N/S N/S N/S N/S N/S
James P. Blackmur,
Neil U. Maitra,
Rajendar R. Marri et al.
462 N/S Ureteric—212 (45.9%);
renal—250 (54.1%)
240 (56%) Majority
30–40 min
83.40% N/S
Dessyn JF, Balssa L,
Chabannes E et al.
497 9.3 Ureteric—126 (25.3%);
renal—398 (79.7%);
multiple—118 (23.7%)
377 (75.9%) 96.8 68% N/S
Berardinelli F, De
Francesco P, Marchioni
M et al.
403 12.21 ± 5.31 N/S 322 (79.9&) 62.42 70.7% N/S
Nevo A, Mano R,
Baniel J et al.
1256 8 (7–12) N/S 239 (19%) 45 N/S N/S
Somani BK, Giusti G,
Sun Y et al.
11,885 N/S Ureteric—69.6%; renal—
18.1%; mixed—8.9%
2263(19%) 40.7 85.8% 7.2%
Ghosh A, Oliver R,
Way C, White L,
Somani BK
544 14.3 (10.9–34.3) Multiple—25.9%;
renal—57.9%;
ureteric—43.6%;
lower pole—28.3%
206 (38%) 46.6 94.2% 9 (1.65%)
Stauffer CE, Snyder E,
Ngo TC et al.
467 9.2 N/S N/S N/S N/S N/S
C Senocak, C Ozcan,
T Sahin et al.
492 13 (10–16) Ureteric—18.0%;
renal—81.8%
458 (93.1%) 57 N/S 61 (12.4%)
Uchida Y, Takazawa R,
Kitayama S et al.
469 10 (3–47) Renal—77 (16.4%);
ureteric—392
(83.5%)
N/S 64 84.4 N/S
Southern JB, Higgins
AM, Young AJ et al.
3298 N/S Ureteral—32.7%;
renal—43.4%;
both—23.9%
2183 (66.2%) 49 N/S N/S
Paper Stone-
free
rate (%)
Infectious complications (n) (%) Total
complications
(n) (% of N)
Overall grade of complications
(n) (% of n)
Fever SIRS UTI Sepsis Total
Pricop C, Dorobăt C,
Puia D et al.
N/S 108 (22.8%) N/S N/S N/S 108 (22.8%) 108 (22.8%) Grade I—108 (22.8%)
Martov A, Gravas S,
Etemadian M et al.
90.80% 27 (1.0%) N/S 17 (0.64%) N/S 44 (1.66%) 170 (6.41%) Grade I—26 (1.58%); grade II—16
(0.6%); grade IIIa—6 (0.23%);
grade IIIb—7 (0.26%); grade
IVa—4 (0.11%); grade IVb—0;
grade V—2 (0.08%)
Özsoy M, Acar Ö,
Sarica K et al.
87% N/S N/S 18 (1.9%) 1 (0.1%) 19 (2.0%) 17.20% Grade I—51 (5.5%); grade II—21
(2.2%); grade IIIa—26 (2.8%);
grade IIIb—60 (6.5%); grade
IV—1 (0.1%)
Moses RA, Ghali FM,
Pais VM Jr. et al.
N/S N/S N/S 19 (3.4%) N/S 19 (3.4%) 47 (8.50%) N/S
James P. Blackmur,
Neil U. Maitra,
Rajendar R. Marri et al.
83.40% N/S N/S N/S 34 (7.4%) 34 (7.4%) Grade IV—33 (7.1%); grade
V—1 (0.22%)
Dessyn JF, Balssa L,
Chabannes E et al.
68% N/S N/S N/S 1 (0.2%) N/S 55 (11%)
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Data Extraction and Analysis
Data was extracted for journal title, author’s details, year of pub-
lication, country of origin, patient demographics, stone charac-
teristics, overall and infection-related complications. Where the
infectious complications were reported separately, it was record-
ed as such. The severity of complications was also categorised
according to the Clavien-Dindo classification system for grading
complications [32]. Studies which described risk factors for post-
URS infection, prevention and management strategies for post-
URS infections were also recorded. All data was recorded using
Microsoft Excel 2019 (version 16.28).
Results
A total of 2070 articles were initially identified, and 14 full-text
English language articles were included in the final reviewwhich
fit our inclusion criteria (Fig. 1) [13, 15, 18–28]. The total num-
ber of ureteroscopies included in these papers was 24,373, and
the mean age was 51.2 years (range 42–61 years), male:female
ratio of 3:2 and a mean BMI of 26.9 (range 23.7–31.8) (Table 1).
All patients’ demographic and procedure details were explored
as possible risk factors for post-ureteroscopy infections (Table 2).
These were gender, stone size or total stone burden, stone loca-
tion, ureteral access sheath use and mean operative time. Other
risk factors included patient comorbidities, history of recurrent
UTIs or positive urine culture, immunocompromised patients,
longer procedural time, pre-operative stent dwell time, previous
indwelling catheter or neurogenic bladder Table 3).
For the papers whichmentioned the stone size and location,
the mean stone size (stone length) was 10.5 mm (range 8–
14.3 mm). The stone location was reported in 9 papers of
which 54% (n = 13,148) were ureteric stones, 22% (n =
5373) were renal stones, 8.6% (n = 2115) were in multiple
locations and in 15.4%, it was not reported. A ureteral access
sheath use was used in 25.8% (n = 6288) patients and ranged
across studies from 206 to 2263 cases. The mean operating
time was 52.7 min (range 40–62.4 min). The stone-free rate
across studies was 83% (range 68–84.4%).
The total number of complications were noted in 7.9% (n =
1919), of which 3.9% (n = 972) were infectious complications
and 4% (n = 1147) were non-infectious complications. Of all
the infectious complications, fever was reported in 66% (n =
642). Urosepsis was reported in 7 papers, and there were 126
patients with urosepsis which was 0.51% of the whole cohort
and 6.5% of the total reported complications.
Of the complications, grade I complication was reported in
67.6% (n = 1298), grade II complication in 14.3% (n = 275),
grade IIIa complication in 5% (n = 98), grade IIIb complica-
tion in 4.2% (n = 82), grade IV complication in 4.7% (n = 91)
and grade V complication in 0.15% (n = 3) patients.
Discussion
Our systematic review for high-volume centres shows a post-
URS urosepsis rates of 0.51%. Antibiotic prophylaxis was prac-
ticed in most of the included studies and offers to reduce this risk
[12]. It seems that there are several pre-disposing factors which
Table 2 (continued)
Grade I—16 (3.2%); grade II—37
(5.4%); grade III—0; grade
IV—1 (0.2%)
Berardinelli F, De
Francesco P, Marchioni
M et al.
70.7% 18 (4.4%) 7 (1.7%) 3 (0.7%) 3 (0.7%) 31 (7.7%) 7.7% Grade I—18 (4.4%); grade II—10
(2.5%); grade IIIa—34 (8.4%)
Nevo A, Mano R,
Baniel J et al.
N/S N/S N/S N/S 36 (2.9%) N/S 36 (2.9%) Grade IV—36 (2.9%)
Somani BK, Giusti G,
Sun Y et al.
85.8% 204 (1.72%) N/S 113 (0.95%) 36 (0.3%) 353 (3.0%) 874 (7.35%) Grade I—141 (1.2%); grade
II—152 (1.3%); grade IIIa—31
(0.26%); grade IIIb—14 (0.12%);
grade IVa—11 (0.09%); grade
IVb—1 (0.008%); grade IV—5
(0.042%)
Ghosh A, Oliver R,
Way C, White L,
Somani BK
94.2% N/S N/S 4 (0.7%) 9 (1.65%) 13 (2.4%) 22 (4%) Grade I—8 (1.5%); grade II—12
(2.2%); grade III—1 (0.18%);
grade IV—0.18%
Stauffer CE, Snyder E,
Ngo TC et al.
N/S N/S N/S 10 (2.1%) N/S 10 (2.1%) 10 (2.1%) Clavien I—10 (2.1%)
C Senocak, C Ozcan,
T Sahin et al.
N/S 14 (2.8%) 23 (4.7%) N/S 5 (1.0%) 42 (8.5%) 22.1% N/S
Uchida Y, Takazawa R,
Kitayama S et al.
84.4 42 (8.9%) 27 (5.7%) N/S 1 70 (14.9%) 70 (14.9%) Grade I—42 (8.9%); grade II—27
(5.7%); grade IV—1 (0.2%)
Southern JB, Higgins
AM, Young AJ et al.
N/S 229 (6.9%) N/S N/S 229 (6.9%) 229 (6.9%) Grade I—229 (6.9%)
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increases this risk and includes positive pre-operative UTI or
prior history of UTIs, patients with higher Charlson comorbidity
index or elderly patients, female gender, presence and duration of
indwelling ureteric stents, procedural time and patients with a
neurogenic bladder and with high BMI [18–28]. Infectious
complications vary from fever, urinary tract infection, pyelone-
phritis, systemic inflammatory response syndrome and urosepsis.
Antibiotics should therefore be tailored to local resistance profiles
which tend to reduce rates of infection and urosepsis [33].
Baboudjian et al. propose that limiting operative times and
Table 3 Infectious complications from the studies including risk factors, modifiable strategies and proposed management of complications (as
mentioned by authors)
Author Risk factors Risk modification strategies Details of complications management
Pricop C. et al. • Absence of antibiotic prophylaxis
• Stone size 0.9–1.2 cm
• Antibiotic prophylaxis N/S
Martov A. et al. • Female gender
• High ASA score
• Older age
• Long pre-operative hospital stay
• Deficient nutritional status
• History of recurrent UTIs
• Impaired immune response
• Bowel surgery
• Diabetes mellitus
• Smoking
• Urinary obstruction
• Lack of control of risk factors
• Antibiotic prophylaxis for all
patients undergoing URS
N/S
Özsoy M. et al. • Female gender N/S N/S
Moses RA. et al. • Longer OR time
• Pre-operative stent
• Understanding local resistance
patterns
• Antibiotic prophylaxis
• Choose broadened prophylaxis,
in pre-stented and longer operations
N/S
James P. et al. • Positive pre-operative culture N/S • 1 case ITU—death
Dessyn JF. et al. • Stone size and number N/S N/S
Berardinelli F. et al. • Coronary heart disease
• Anticoagulant therapy
• CKD
• Alteration of lipid metabolism
• Presence of residual fragments
• Past surgery for renal stone
N/S • Fever—antipyretics
• SIRS—Abx, IV fluids
• Sepsis—Abx, IV fluids, Inotropes
• Obstructive pyelonephritis—DJ placement
• Hospital re-admission, 1.2%
Nevo A. et al. • Female gender
• Pre-operative stent long indwelling time
N/S N/S
Somani BK. et al. N/S N/S N/S
Ghosh A. et al. • Long hospital stay
• Older age
• Positive pre-operative culture
• Longer OR time
N/S • Sepsis managed with IV antibiotics;
• 1 case—ITU for candidaemia
Stauffer CE. et al. • Neurogenic bladder
• Indwelling catheter
• Bacterial colonization
N/S N/S
Senocak C. et al. • Positive pre-operative MDR culture N/S N/S
Uchida Y. et al. • Female gender
• Lower BMI
• Deficient nutritional status
• Previous obstructive pyelonephritis
• Positive pre-operative culture
• Struvite stones
• Pre-operative stent
N/S • 1 case—ITU with vasopressors
Southern JB. et al. • Female gender
• Longer OR time
• Multiple comorbidities
• Positive pre-operative culture
• Pre-operative counselling • Sepsis—ward-based management
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treating pre-operative UTI should lead towards reduced post-
operative infection rates [29].
There is a substantial patient and economic cost associated
with sepsis, which is > $24 billion per year in the USA alone
[34]. Urosepsis leads to morbidity and mortality and hence,
prevention, early detection and management are paramount
[14]. It is the leading cause of mortality for patients with
KSD and is more common in patients with comorbidities,
high stone burden, obesity, with spinal cord injury or neuro-
genic bladders. The CROES study revealed a mortality rate of
0.04%which confirms that although the mortality rate of URS
is negligible, but, it is not zero, and all precautions must be
taken for it [13]. Prevention strategies included the use of
prophylactic antibiotics, aggressive treatment of pre-
operative UTIs, reducing operating duration, caution in elder-
ly and patients with high stone burden [14].
Previous work by Traxer et al. showed that the use of ure-
teral access sheath (UAS) helps to reduce post-URS infectious
complication [35]. However, the use of UAS was not helpful
in reducing infectious complications in another study looking
at treatment of large renal stones [36]. The presence of in-
dwelling stents more than 1 month was associated with a
higher risk of sepsis [20•]. Hence, any pre-procedural ureteric
stent must be kept as short as possible prior to offering a
definitive ureteroscopy.
In patients with urosepsis due to obstructed ureteric stone,
an immediate drainage via a nephrostomy or ureteric stent is
needed, in addition to antibiotics and supportive care [37]. A
delayed ureteroscopy and stone treatment in these cases lead
to good clinical outcome [37].
Urosepsis-related mortality was found to be 2.5 times
higher in patients with urinary obstruction and is largely due
to urolithiasis [38]. Urgent decompression in obstructed
calculus-related sepsis is warranted; otherwise, the mortality
is doubled, and this drainage should be early (within 48 h) to
reduce the hospital stay [39, 40]. Although there is no consen-
sus on the time duration between emergency drainage and
elective ureteroscopy, it is generally agreed that this should
be as soon as the patient has recovered from the initial sepsis
and is stable to undergo the ureteroscopy [37].
Conclusion
Infectious complications following ureteroscopy can be a
source of morbidity and potential mortality. Although major-
ity of these are minor, efforts must be taken to minimize them
especially in high-risk patients. This includes use of prophy-
lactic antibiotics, limiting stent dwell and procedural time,
prompt identification and treatment of UTI and urosepsis,
and careful planning in patients with large stone burden and
multiple comorbidities.
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